Telavancin and vancomycin had similar cure rates, 72% and 73%, respectively, for skin and skin structure infections in obese patients, though the serious adverse event rate was higher in the telavancin group (11% compared with 3%), according to an analysis of two late-stage trials. "If you have a patient who has a complicated skin infection for whom other agents that are available might not be an option, telavancin is something you can consider, even in obese patients," said study leader Christine M. Slover. However, severely obese people often have peripheral vascular disease, and curing SSSIs may be difficult regardless of which antibiotic is used, Slover said.

Full Story:
Dermatology News

Related Summaries